Company intelligence / Profile preview

Dongkook Pharmaceutical

Gangnam-gu, Seoul, South Koreadkpharm.co.kr ↗

Overview

Dongkook Pharmaceutical has a diverse pipeline with several programs in preclinical to Phase III stages. Notably:

DKF-313 for BPH in Phase III clinical trials.
DKF-335 for postmenopausal osteoporosis in Phase I. The company also markets a wide range of prescription and OTC drugs domestically and internationally. It leverages both traditional R&D and AI-driven platforms for new drug discovery[3][8][9][10].

Therapeutic areas: PulmonologyCardiovascularMen's HealthRheumatologyEndocrinologyNeurology
Modalities: Small moleculescombination drugsdepot injectionslong-acting injectablesbiomaterials
Industry: Biotech

13 assets

12 more assets in the full pipeline.

Oncovix—AI-driven natural product-based drug discovery using TOFPOMICS platform technology.

Beyond the preview

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Follow clinical development from trial design and recruitment through results.

Explore licensing agreements, acquisitions, and the assets behind each deal.

Trace financing activity and the investors behind a company’s development.

Compare peer pipelines by target, modality, and therapeutic area.

Explore technology platforms and the patent landscape around relevant assets.

Connect company news and source material to the questions you’re investigating.

See how Gosset can support your research on Dongkook Pharmaceutical.